New drugs for the treatment of osteogenesis imperfecta: Research advances

Fang Lv; Mei Li

doi:10.13220/j.cnki.jipr.2017.02.016

New drugs for the treatment of osteogenesis imperfecta: Research advances

Fang Lv
, Mei Li^*

^*此作品的通讯作者

Chinese Academy of Medical Sciences

科研成果: 期刊稿件 › 文章 › 同行评审

摘要

Osteogenesis imperfecta(OI)is a genetic bone disease characterized by increased bone fragility and recurrent bone fractures. It belongs to orphan diseases of which the diagnosis and treatment are facing challenges. The effective treatments targeting at the underlying causes are still unavailable. Recently, many agents have been demonstrated to increase bone mineral density, improve bone microstructures, and reduce the incidence of fractures. Herein, we review the progress in new drugs for the treatment of OI.

源语言	英语
页（从-至）	173-177
页数	5
期刊	Journal of International Pharmaceutical Research
卷	44
期	2
DOI	https://doi.org/10.13220/j.cnki.jipr.2017.02.016
出版状态	已出版 - 28 2月 2017
已对外发布	是

访问文件

10.13220/j.cnki.jipr.2017.02.016

其它文件与链接

链接到 Scopus 的出版物

引用此

@article{862dabadaad84be4ab710221bd2d8ad6,

title = "New drugs for the treatment of osteogenesis imperfecta: Research advances",

abstract = "Osteogenesis imperfecta(OI)is a genetic bone disease characterized by increased bone fragility and recurrent bone fractures. It belongs to orphan diseases of which the diagnosis and treatment are facing challenges. The effective treatments targeting at the underlying causes are still unavailable. Recently, many agents have been demonstrated to increase bone mineral density, improve bone microstructures, and reduce the incidence of fractures. Herein, we review the progress in new drugs for the treatment of OI.",

keywords = "Orphan drug, Osteogenesis imperfect, Rare disease",

author = "Fang Lv and Mei Li",

year = "2017",

month = feb,

day = "28",

doi = "10.13220/j.cnki.jipr.2017.02.016",

language = "English",

volume = "44",

pages = "173--177",

journal = "Journal of International Pharmaceutical Research",

issn = "1674-0440",

publisher = "Editorial office of Journal of International Pharmaceutical Research",

number = "2",

}

TY - JOUR

T1 - New drugs for the treatment of osteogenesis imperfecta

T2 - Research advances

AU - Lv, Fang

AU - Li, Mei

PY - 2017/2/28

Y1 - 2017/2/28

N2 - Osteogenesis imperfecta(OI)is a genetic bone disease characterized by increased bone fragility and recurrent bone fractures. It belongs to orphan diseases of which the diagnosis and treatment are facing challenges. The effective treatments targeting at the underlying causes are still unavailable. Recently, many agents have been demonstrated to increase bone mineral density, improve bone microstructures, and reduce the incidence of fractures. Herein, we review the progress in new drugs for the treatment of OI.

AB - Osteogenesis imperfecta(OI)is a genetic bone disease characterized by increased bone fragility and recurrent bone fractures. It belongs to orphan diseases of which the diagnosis and treatment are facing challenges. The effective treatments targeting at the underlying causes are still unavailable. Recently, many agents have been demonstrated to increase bone mineral density, improve bone microstructures, and reduce the incidence of fractures. Herein, we review the progress in new drugs for the treatment of OI.

KW - Orphan drug

KW - Osteogenesis imperfect

KW - Rare disease

UR - https://www.scopus.com/pages/publications/85016214849

U2 - 10.13220/j.cnki.jipr.2017.02.016

DO - 10.13220/j.cnki.jipr.2017.02.016

M3 - Article

AN - SCOPUS:85016214849

SN - 1674-0440

VL - 44

SP - 173

EP - 177

JO - Journal of International Pharmaceutical Research

JF - Journal of International Pharmaceutical Research

IS - 2

ER -

New drugs for the treatment of osteogenesis imperfecta: Research advances

摘要

访问文件

其它文件与链接

指纹

引用此